secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001558370-23-003866
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor reports Q4 2022 net loss $7.7M ($0.31/share); expands Nippon Shinyaku deal to Japan for $12M upfront
--------------------------------------------------------------------------------

- Q4 2022 revenue $1.0M (Nippon Shinyaku upfront recognition) vs $0; net loss $7.7M vs $6.2M in Q4 2021.
- Full-year 2022 net loss $29.0M ($1.18/share) vs $20.0M ($0.87/share); cash $41.4M as of Dec 31, 2022.
- HOPE-3 Phase 3 trial for CAP-1002 in DMD >30% enrolled; interim analysis expected Q4 2023.
- Japan partnership with Nippon Shinyaku: $12M upfront, up to $89M milestones, double-digit net revenue share.
- Cash runway projected into Q4 2024, including $12M Japan upfront expected in Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023003866/0001558370-23-003866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023003866/capr-20230315x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-003866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer